Concepedia

Randall Schreck

RS

Statistics

Publications

10

Citations

4.7K

H-Index

10

Active since

1994

Affiliations

Maxygen (United States)(Current)

Randall Schreck is an author at Maxygen (United States) specializing in pharmacology, medicine, and oncology.

Publications per year

1994–2003

10

Publications

10

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

, , +15

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

T. Annie T. Fong, Laura K. Shawver, Li Sun et al. · PubMed · 1999 · 1K citations

, , +16

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

James G. Christensen, Randall Schreck, Jon Burrows et al. · PubMed · 2003 · 497 citations

, , +15

Flk-1 as a target for tumor growth inhibition.

L M Strawn, Gerald McMahon, Harald App et al. · PubMed · 1996 · 318 citations

, , +15

Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases

Li Sun, Ngoc Quang Tran, Congxin Liang et al. · Journal of Medicinal Chemistry · 1999 · 272 citations · Full text

, , +17

1–5 of 10